In this article, we will list the 5 Best IPO Stocks with Huge Upside Potential. Please visit 12 Best IPO Stocks with Huge Upside Potential to see the extended list and the methodology behind it.
5. Oklo Inc. (NYSE:OKLO)
Average Upside Potential: 75.54%
Oklo Inc. (NYSE:OKLO) is one of the best IPO stocks with huge upside potential. On June 30, Oklo announced the acquisition of Creative Engineers/CEI, a chemical process engineering firm with specialized expertise in sodium and alkali-metal systems. This move integrates CEI’s capabilities in component development, fabrication, and applied R&D into Oklo’s team to directly support its sodium-cooled Aurora powerhouse technology.
Founded in 1996, CEI has decades of experience working with liquid-metal systems and has served as a technical partner to Oklo for several years. By bringing this team of approximately 20 engineers and fabricators in-house, Oklo aims to accelerate design iterations, enhance safety training, and reduce execution risks associated with its reactor deployment.
The acquisition adds a free cash flow positive business to Oklo Inc.’s (NYSE:OKLO) operations while allowing the company to internalize critical engineering and testing functions. CEI intends to continue its longstanding service relationships across the broader nuclear sector while focusing its primary efforts on advancing the commercialization of Oklo’s advanced nuclear energy solutions.
Oklo Inc. (NYSE:OKLO) is engaged in developing advanced fission power plants to offer clean, reliable, and affordable energy at scale.
4. AEVEX Corp. (NYSE:AVEX)
Average Upside Potential: 78.57%
AEVEX Corp. (NYSE:AVEX) is one of the best IPO stocks with huge upside potential. On July 6, AEVEX announced a $17.5 million follow-on contract to provide mission-focused, data-driven services in support of US national security objectives. The award reinforces the company’s role in delivering specialized expertise and integrating multi-domain solutions to transform complex data into actionable insights for time-sensitive operations.
Before that, on June 30, AEVEX announced the appointment of Murali Krishnan as Chief Growth Officer. Bringing over two decades of executive experience in defense technology and national security, Krishnan will lead the company’s global business development, strategic partnerships, and long-term market expansion initiatives.
In his new role, Krishnan will collaborate with the executive leadership team to accelerate growth across AEVEX Corp.’s (NYSE:AVEX) portfolio of unmanned systems and advanced mission solutions. Previously, he held senior leadership positions at Northrop Grumman, where he oversaw expansive portfolios in space systems, sensor solutions, and strategic growth for defense and civil programs.
AEVEX Corp. (NYSE:AVEX) is a leading US defense firm specializing in autonomous systems, AI-driven software, and advanced electronic warfare for national security. Through rapid prototyping and high-volume manufacturing, the company delivers affordable, front-line-ready solutions designed to maintain technological superiority in contested environments.
3. Kailera Therapeutics Inc. (NASDAQ:KLRA)
Average Upside Potential: 80.26%
Kailera Therapeutics Inc. (NASDAQ:KLRA) is one of the best IPO stocks with huge upside potential. On July 7, Kailera Therapeutics announced positive topline results from two Phase 3 clinical trials conducted by Hengrui Pharma for HRS-7535/KAI-7535, an oral small-molecule GLP-1 receptor agonist. In the obesity trial, participants achieved a mean weight loss of up to 10.9% by Week 44 and 11.1% by Week 50, while the type 2 diabetes trial demonstrated a mean HbA1c reduction of 1.50% to 1.68%.
Liver safety findings across both trials remained consistent with prior data, showing no observed safety signals. These results underscore the potential for the oral treatment to offer a convenient and scalable alternative for patients, maintaining efficacy while providing a favorable safety profile.
Concurrent with these developments, Kailera Therapeutics Inc. (NASDAQ:KLRA) is advancing KAI-7535 through a global Phase 2 clinical trial that began in April 2026. This study aims to further optimize the drug’s clinical profile for obesity treatment by assessing a broad range of doses and titration strategies, with results expected in 2027.
Kailera Therapeutics Inc. (NASDAQ:KLRA) is a clinical-stage biotechnology company dedicated to advancing a diversified pipeline of obesity treatments, including four clinical-stage candidates. The company’s portfolio leverages various GLP-1-based mechanisms to provide flexible, effective options for weight management across different stages of a patient’s journey.
2. HawkEye 360 Inc. (NYSE:HAWK)
Average Upside Potential: 100.30%
HawkEye 360 Inc. (NYSE:HAWK) is one of the best IPO stocks with huge upside potential. On June 22, HawkEye 360 reported record financial results for FQ1 2026, highlighted by a 116.5% year-over-year revenue increase to $49.8 million. The company also reported an adjusted EBITDA of $7.4 million, a 92.1% increase from the prior year, and a total backlog of $285 million.
During the quarter, HawkEye 360 Inc. (NYSE:HAWK) completed an initial public offering in May, raising $435.9 million in net proceeds. This financial milestone, alongside a new $125 million revolving credit facility, provides the company with significant flexibility to support its ongoing constellation expansion and strategic growth initiatives.
Operational highlights include the successful launch of six satellites across Clusters 13 and 14 and over $100 million in new international contract awards so far in 2026. These developments, including a recent $75 million electronic warfare program with a European Ministry of Defense, underscore the rising global demand for the company’s space-based signals intelligence and analytics.
HawkEye 360 Inc. (NYSE:HAWK) provides mission-critical signals intelligence by detecting and geolocating global radio-frequency emissions to support faster decision-making for defense and national security. Through space-based collection and AI-powered analytics, the company transforms RF spectrum data into a strategic advantage for the US government and allied partners.
1. WeRide Inc. (NASDAQ:WRD)
Average Upside Potential: 109.59%
WeRide Inc. (NASDAQ:WRD) is one of the best IPO stocks with huge upside potential. On June 22, WeRide, Geely Farizon, and Kwoon Chung Bus Holdings announced a partnership to develop robotaxis specifically designed for right-hand-drive markets.
By integrating WeRide’s autonomous driving technology with Geely Farizon’s vehicle manufacturing and Kwoon Chung’s operational expertise, the companies aim to launch a mass-produced, purpose-built vehicle based on the GXR platform, with initial deployments beginning in Hong Kong.
This initiative addresses the global shortage of right-hand-drive autonomous solutions and serves as a strategic gateway for WeRide Inc. (NASDAQ:WRD) to expand into markets such as Singapore, the United Kingdom, Japan, and Australia. The project aligns with China’s five-year development plan for intelligent new energy vehicles and supports WeRide’s goal of scaling its global fleet to 2,600 vehicles by the end of 2026.
WeRide Inc. (NASDAQ:WRD) is a global leader in autonomous driving technology that develops and deploys L2-L4 self-driving solutions, focusing on robotaxis, intelligent driving, and smart mobility. It provides driverless services for mobility, logistics, and sanitation industries, including Robotaxis, Robobuses, Robovans, and Robosweepers.
While we acknowledge the potential of WRD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than WRD and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Best New Tech Stocks to Buy According to Analysts and 10 Best Up and Coming Stocks to Buy for the Next 3 Years.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
